Minnesota's war on Christians continues…

Christian colleges sue after being snubbed from Minnesota's dual enrollment program.

Minnesota Christian colleges are challenging the state after a decades-long law was amended to exclude them from participating in the state’s dual enrollment program because they require students to sign statements of faith.

Since 1985, Minnesota’s postsecondary enrollment program allowed thousands of high school students, desiring to attend both private and public colleges, to enroll in a program and simultaneously receive high school and college credits for free. In 2023, the state amended the program law to exclude schools that require students to sign a statement of faith on the application, a decision that would single out Christian universities, according to legal representation. Now, the colleges are fighting the measure, saying it discriminates on the basis of religious exercise.

https://www.msn.com/en-us/news/us/christian-colleges-sue-after-being-snubbed-from-minnesota-s-dual-enrollment-program/ar-AA1xSQpR

Pharma is hopeful about Trump's second term, here's what to expect for drugmakers.

President Donald Trump will make lowering health-care costs for Americans a priority. It's a popular bipartisan issue in a nation where patients pay two-to-three times more for prescription drugs than people in other developed countries. Trump has not yet outlined specific health policy plans, but his new administration will likely take a different, more pro-business approach than Biden's did.

Trump will focus more on cracking down on middlemen called pharmacy benefit managers and promoting drug innovation and improving patient access to treatments. Those companies are particularly eager to see changes to Biden's Inflation Reduction Act, which threatens innovation and less competition.

That was the sentiment during the JPMorgan Health Care Conference in San Francisco this month, the largest gathering in the U.S. of pharma and biotech executives and investors. The annual conference gives a pulse on the industry's outlook for the year ahead. To no surprise, health policy questions dominated many of the conversations as Trump was heading into office.

https://www.msn.com/en-us/health/other/pharma-is-hopeful-about-trump-s-second-term-here-s-what-to-expect-for-drugmakers/ar-AA1xT3Yt